



EDITORIAL COMMENT

A large-scale biobank and more genome-wide association studies of cardiovascular disease are needed in Portugal



Um biobanco em grande escala e mais estudos de associação do genoma das doenças cardiovasculares são necessários em Portugal

Rui Providência^{a,b}

^a Institute of Health Informatics Research, University College London, London, United Kingdom

^b Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom

Available online 22 April 2025

Nearly 20 years ago, following the completion of the Human Genome Project and advances in high-throughput genotyping technologies, the first genome-wide association studies (GWAS) were published.¹ GWAS identify associations between genetic variants (single nucleotide polymorphisms [SNPs]) and phenotypical traits using an agnostic approach and became more common with the development of SNP arrays.

Among their many potential applications, GWAS findings help (i) discover potential drug targets,² (ii) develop or improve risk prediction models,^{3,4} and (iii) refine population sub-phenotyping, enabling the paradigm of personalized medicine and the tailoring of prevention and treatment based on genetic risk.⁵

Progress in the field has been exponential, driven by a dramatic reduction in the cost of genotyping using high-density SNP arrays over the past 20 years, now priced at less than €50 per sample. Additionally, the power of discovery has significantly increased as studies have expanded beyond

small cohorts to include large international consortia and nation-scale biobanks.⁶

Genome-wide association studies of Portuguese cohorts are scarce⁷ and there is reduced collaboration in international consortia. Despite this, the GENES in MAdeira and CORonary Disease (GENEMACOR) study is a solid example of a national cohort assessing the impact of genetic variants in cardiovascular outcomes. This cohort has provided invaluable landmark contributions to the cardiovascular field.^{8,9} In this issue of the Portuguese Journal of Cardiology, Sá et al. assessed a cohort of 1284 asymptomatic GENEMACOR participants without coronary artery disease using the coronary artery calcium score. The authors determined which of the 33 assessed genetic variants were independently associated with coronary artery calcification: *PHACTR1* rs1332844, a downstream regulator of the endothelin-1 gene, *CDKN2B-AS1* rs4977574, an epigenetic regulator, and *MTHFD1L* rs6922269, involved in de novo thymidylate biosynthesis, were the identified candidates.¹⁰

More cohorts with biological samples for GWAS should be established nationally. The creation of a large-scale Portuguese biobank should be a number one priority for health research in the coming years. GWAS have predominantly focused on individuals of European descent, resulting in

DOI of original article:

<https://doi.org/10.1016/j.repc.2025.01.003>

E-mail address: r.providencia@ucl.ac.uk

✉ [@rui.providencia](https://twitter.com/rui.providencia)

<https://doi.org/10.1016/j.repc.2025.04.002>

0870-2551/© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

significant disparities in genetic research, and potential issues regarding generalizability of the findings. Therefore, it is important that individuals with African and South American ancestry are well-represented in this project. This is of paramount importance for advancing our understanding not only of coronary artery disease, heart failure, and atrial fibrillation, but also of often-overlooked rheumatic heart disease, which still causes 345 000 deaths annually. Insights from the East London Genes & Health cohort,¹¹ which addresses the underrepresentation of South Asian individuals in genetic research and explores potential contributors to the increased cardiometabolic risk in this population, will be valuable.

Funding

RP is supported by the UCL BHF Research Accelerator AA/18/6/34223, NIHR grant NIHR129463 and UKRI/ERC/HORIZON 10103153 Aristoteles.

Conflicts of interest

None declared.

References

1. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005;308:385–9.
2. Kukendrarajah K, Farmaki AE, Lambiase PD, et al. Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies. *EBioMedicine*. 2024;105:105194.
3. Mendonça MI, Henriques E, Borges S, et al. Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population. *Genet Mol Biol*. 2021;44, e20200448.
4. Temtem M, Mendonça MI, Gomes Serrão M, et al. Predictive improvement of adding coronary calcium score and a genetic risk score to a traditional risk model for cardiovascular event prediction. *Eur J Prev Cardiol*. 2024;31:709–15.
5. O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2022;146:e93–118.
6. Roselli C, Surakka I, Olesen MS, et al. Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases. *Nat Genet*. 2025;57:539–47, <http://dx.doi.org/10.1038/s41588-024-02072-3>.
7. Abrantes P, Santos MM, Sousa I, et al. Genetic variants underlying risk of intracranial aneurysms: insights from a GWAS in Portugal. *PLoS One*. 2015;10:e0133422.
8. Santos MR, Mendonça MI, Temtem M, et al. Transcription factor 21 gene and prognosis in a coronary population. *Rev Port Cardiol*. 2023;42:907–13.
9. Mendonça MI, Pereira A, Monteiro J, et al. Impact of genetic information on coronary disease risk in Madeira: the GENEMACOR study. *Rev Port Cardiol*. 2023;42:193–204.
10. Sá D, Mendonça MI, Serrão M, et al. Unraveling the genetic basis of subclinical atherosclerosis: early genetic detection can improve cardiovascular prevention. *Rev Port Cardiol*. 2025;44:351–8.
11. Finer S, Martin HC, Khan A, et al. Cohort profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. *Int J Epidemiol*. 2020;49, 20–21i.